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Abstract
Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 
treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 
KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 
55.5±8.4 years, a median time from transplantation of 3611 days (1465-5757); 5/6 had 
cardiovascular comorbidities, 1/6 had diabetes and 3/6 have one or more previous  KTs.
Four out of six patients died, at an average time of 9.75±2.4 days after tocilizumab administration, 
3/6 due to a coexistent septic shock. Two patients improved after TCZ and were discharged at 20 
and 21 days respectively; in both patient a significant increase of total lymphocyte count was 
observed.
In conclusion KTs, where the role of peculiar factors such as chronic immunosuppression is still 
undetermined, represent a high-risk group with significant COVID-19 associated mortality. The 
evaluation of the TCZ effect in COVID-19 pneumonia requires controlled studies (ideally RCTs) 
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Background
Severe acute respiratory syndrome coronavirus 2 (named SARS CoV-2/COVID-19) is a novel 
pandemic infectious disease, which emerged in Wuhan, China, in late December 2019 and spread 
rapidly worldwide1,2. At the time we are writing (05/10/2020) in Italy there are about 219000 
patients infected, 28600 only in Piedmont, our region3. Clinically, the disease is characterized with 
fever, cough, dyspnea, diarrhea and eventually respiratory failure4,5. According to their intrinsic 
frailty and comorbidities, transplanted patients were considered a high-risk population6,7.
Tocilizumab (TCZ), a humanized monoclonal antibody against Interleukin-6 (IL-6) receptor 
widely adopted in adult rheumatoid arthritis and also used as rescue therapy for chronic antibody-
mediated rejection in kidney transplantation8, has been recently registered for the treatment of 
severe or life-threatening chimeric antigen receptor T-cell induced cytokine release syndrome 
(CRS) in adult and pediatric patients9. In this context, because the development of acute 
respiratory distress syndrome (ARDS) in COVID-19 pneumonia has been associated with 
activation of the immune system and consequent cytokine storm with high levels of IL-6, some 
initial reports suggested a beneficial role of this drug10,11, also in solid organ transplanted 
patients12. Herein we reported our experience in 6 kidney transplanted patients treated with TCZ 
after occurrence of COVID-19 infection.
Case series
Clinical characteristics and laboratory data are shown in Table 1 and 2. Figure 1 reported the 
timeline of maintenance immunosuppression, COVID-19 specific treatments and outcome. In all 
patients, diagnosis was performed by nasopharyngeal swab test (PCR) and chest radiography or 
high-resolution computed tomography (HRCT). TCZ was administered once daily for two 
consecutive days (dose 8 mg/kg) after a consultation with infectious disease specialist in patients 
with contemporary evidence of pulmonary involvement (oxygen saturation - Sa02 - <93% if 
patients breath ambient air, or a ratio of the partial pressure of oxygen -PaO2- to the fraction of 
inspired oxygen - FiO2- of less than 300 mm Hg) and pro-inflammatory profile (C-reactive protein 
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41 years old patient. He received kidney transplant from deceased donor 15 years ago. Ongoing 
immunosuppressive therapy was composed by tacrolimus (TAC) and prednisone.
After few days of fever and cough patient was tested positive for COVID-19 on 03/25/2020. TAC 
was immediately discontinued while glucocorticoids (methylprednisolone 20 mg daily) were 
maintained. In the same day of the diagnosis, hydroxycloroquine and antiviral treatment 
(Darunavir/Ritonavir 800/100 mg) were started, in association with antibiotic therapy (cefepime). 
On day 7 after diagnosis, because of rapid worsening of respiratory status, TCZ was administered 
and repeated in day 8; concomitantly, according to progressive deterioration of kidney function 
and difficult management of fluid overload, continuous renal-replacement therapy (CRRT) was 
initiated. Despite the antibiotic therapy implementation with azithromycin, respiratory failure 
occurred needing mechanical ventilation from day 15; patient died two days after. 
Patient 2
65 years old patient. He received kidney transplant from a deceased donor on March 2020. A 
negative COVID-19 test was obtained before kidney transplant, and no positive contact with 
COVID-19 subjects was reported in the days before KT. 
Induction immunosuppressive therapy was composed by Thymoglobulin (for three days) and 
methylprednisolone, and subsequent maintenance therapy included TAC (levels 10-12 ng/mL), 
mycophenolate mofetil (MMF) and prednisone. Patient also received ganciclovir for CMV 
prophylaxis (CMV IgG-/donor CMV IgG+).
Eight days after KT patient experienced fever and cough; swab test was subsequently repeated and 
resulted positive. Immunosuppressive medications (TAC, MMF) were immediately stopped, 
except of glucocorticoids (methylprednisolone 20 mg/day). Patient started hydroxycloroquine (200 
mg daily) and Darunavir/Ritonavir (800/100 mg daily) the day after, and remained 
hemodynamically stable with only slow reduction of peripheral oxygen saturation (94-95% with 
low-flow oxygen through nasal cannula); TCZ was administered on day 4 and 5.
On day 6 arterial pO2 decreased and patient started non-invasive ventilation (NIV); after a further 
deterioration of pulmonary status mechanical ventilation was needed from day 7.
On day 8 blood and urinary cultures were both positive for multi-sensitive Klebsiella Pneumoniae 
(urinary culture was also positive for Enterococcus Faecalis), and antibiotic treatment was shifted 
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Despite progressive modifications on antibiotic therapy (with at least adoption of gentamicin, 
piperacillin/tazobactam and daptomycin), fluid and medication support patient became oliguric 
(starting CRRT from day 12) and died on day 17.
Patient 3
54 years old patient. He received his third kidney transplant in 2014. Ongoing immunosuppressive 
therapy was composed by TAC and glucocorticoids. On 04/03/2020 patient experienced fever, 
emesis and diarrhea, and tested positive for COVID-19. TAC was immediately discontinued, and 
only methylprednisolone 20 mg/daily was maintained in association of hydroxycloroquine (200 
mg/day). On day 2, hemophtoe and worsening of respiratory status occurred. Oral anticoagulant 
therapy (in patient with mechanical aortic valve) was stopped and replaced by low-molecular-
weight heparin, and non-invasive ventilation (NIV) was started. TCZ was administered on day 2 
and 3. On day 12, after an improvement in respiratory condition, NIV was suspended; patient was 
discharged on day 20. Currently (26 days after discharge), he recovered to normal pulmonary 
functional status, keeping only steroids (prednisone 25 mg/day) as immunosuppressive therapy.
Patient 4
62 years old patient. He performed his second KT on 2007. Immunosuppressive therapy was 
composed by TAC, MMF and steroids. On 03/22/2020 patient experienced fever, dyspnea and 
diarrhea and then tested positive for COVID-19. TAC and MMF were immediately discontinued. 
Hydroxycloroquine 200 mg daily, methylprednisolone 20 mg daily and piperacillin-tazobactam, in 
association to fluconazole, were started. A rapid worsening of respiratory status was observed 
from day 1 after diagnosis, needing mechanical ventilation. TCZ was administered (8 mg/kg) on 
day 16; respiratory status showed no improvement and patient deceased on day 26.
Patient 5
49 years old patient. He received kidney transplant 18 years ago. Ongoing immunosuppressive 
therapy was TAC, MMF and glucocorticoids. On 03/24/2020 he was admitted to the Emergency 
Department because fever and cough from two days. After positive swab test, TAC level was 
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On day 4, after progressive worsening of respiratory status, TAC was discontinued and NIV plus 
TCZ were started. On day 11, IVIg (0.2 g/kg/day) were also administered for four consecutive 
days. On day 16 glucocorticoid therapy was increased with methylprednisolone 40 mg twice daily. 
NIV was discontinued on day 17 and the patient was discharged on day 21 after diagnosis.
Currently (12 days after discharge), pulmonary function recovered to basal patient’s status and 
TAC target through level are progressively increased to 4-5 ng/mL with glucocorticoids 
maintained.
Patient 6
62 years old patient. He received KT in 2011. Ongoing immunosuppressive therapy was 
composed by TAC and glucocorticoids. Patient was admitted to Emergency Department on 
04/03/2020 because of fever and dyspnea. After diagnosis of COVID-19 pneumonia, TAC was 
stopped on day 1 and treatment with hydroxycloroquine (200 mg daily) and amoxicillin-clavulanic 
acid (1 g twice daily) were started, in association with methylprednisolone 20 mg daily. 
Mechanical ventilation was also initiated on day 1; TCZ was administered on day 2 and 3. Despite 
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Discussion
COVID-19 is now considered as the most prominent health-care problem around the world13. 
Emerging data highlight the role of comorbid conditions (hypertension, diabetes, cardiovascular 
disease) and older age as major determinants of negative outcome10. Recently, kidney disease has 
also been associated with increased in-hospital mortality14.
Transplant patients, due to the combination of this frail profile associated with immunosuppressive 
medications, are considered a high-risk population15; despite preventive strategies and medication 
protocols are urgently needed, definite guidelines for KT are not currently established and 
different and specular approaches have so far been reported.
Some group suggest the immediately withdrawn of immunosuppressive drugs with only steroid 
maintenance1,16, despite steroid use is controversial and associated with reduced viral clearance17. 
Other authors report a possible anti-viral effect of CNI inhibitors2,4,6,10,18 suggesting per contrast 
their maintenance in solid organ transplanted patients, especially in liver transplants. This theory is 
also supported by the evidence that ARDS occurred in patients with important inflammatory 
activation (the so-called cytokine storm) and in this context immunosuppressive medications and 
anti-inflammatory drug (i.e. TCZ) may mitigate the damage. All these data are partially questioned 
by a recent US report19 were mortality in KT patients is extremely high compared to normal 
population, despite a recent Spanish case-series detailed a more favorable picture20.
To date, few reports included TCZ-treated kidney transplanted patients with COVID-19 
pneumonia12,19-23 (Table 3): in all these available experiences inclusion criteria, dose, f/up and 
outcome indicators were different, and a significant number of cases were still inpatients. 
Despite different timing, in our case series TCZ was administered at the same dosage after 
deterioration of pulmonary status and contemporary evidence of significant inflammatory 
activation (increase C-reactive protein and/or IL-6, if available). The adoption of TCZ determined 
a C-reactive protein reduction in all patients without significant modification in LDH or D-Dimer; 
also IL-6 decreased in the 2/3 patients with available test, albeit levels remain significantly upper 
the normal range. However, four out of six patients died; in the 2/6 who recovered a significant 
increase in lymphocyte count was observed, confirming that a restoration of lymphocyte activity is 
crucial for obtaining a favorable outcome 24.
We need to underline that some factors may be confounding in the analysis of the direct effect of 
TCZ: for example, sepsis may have concurred to death in Patient 1, 4 and 6; however, as reported 
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result of combined inhibition of IL-6 receptor in predisposing to bacterial infections is not well 
understood. We also pointed out that we treated with TCZ only kidney transplanted patients who 
required hospitalization with significant reduction of pulmonary function and increase of 
inflammatory markers. At the time we are writing, 20 patients who received KTs in our Center 
were tested positive for COVID-19, and 8/20 (including 4/8 who received TCZ) died. Because all 
patients with COVID-19 who do not need hospitalization were tested and remained at home we do 
not have laboratory/pulmonary functional markers to compare this cohort to TCZ treated patients.
In conclusion, despite these data should be evaluated with extremely caution and have some 
limitations (selection bias, availability of IL-6 dosage in all patients, absence of CD4+/CD8+ 
count), our study confirmed that kidney transplanted patients are a high-risk group with significant 
COVID-19 associated mortality. The effect of TCZ for COVID-19 pneumonia need of controlled 
studies (ideally RCTs) in this specific population.
Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by the 
Transplant Infectious Disease Journal.
The data that support the findings of this study are available from the corresponding author upon 
reasonable request.
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Figure legend
Figure 1: Therapeutic timeline for anti-COVID-19 and immunosuppressant medications in 
our case series. MP: methylprednisolone; HCQ: hydroxychloroquine; DAR/RIT: 
Darunavir/Ritonavir; TCZ: tocilizumab; TAC: tacrolimus; MMF: mycophenolate mofetil; IVIg: 
intravenous immunoglobulin.
Table legends
Table 1: Clinical characteristics, comorbidities and symptoms at presentation in our COVID-19 
positive kidney transplant recipients.
Table 2: Laboratory and pulmonary functional tests before and after TCZ adoption in our 
COVID-19 positive kidney transplant recipients.
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Table 1. Clinical characteristics, comorbidities and symptoms at presentation in our COVID-19 positive kidney transplant recipients 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Gender Male Male Male Male Male Male 
Age, years 41 65 54 62 49 62 
Previous KT (n) No Yes (1) Yes (2) Yes (1) No No 
Time from last KT, days 5354 8 2053 4681 6411 3163 
Comorbidities       
Hypertension Yes Yes No Yes No Yes 
Diabetes mellitus No Yes No No No No 
Cardiovascular disease No Yes Yes Yes Yes Yes 
HCV infection** No No No Yes Yes No 
Immunosuppressive therapy       
TAC Yes Yes Yes Yes Yes Yes 
MMF No Yes No Yes Yes No 
Steroids Yes Yes Yes Yes Yes Yes 
Symptoms at presentation       
Fever Yes Yes Yes Yes Yes Yes 
Cough Yes Yes No No Yes No 
Dyspnea No No No Yes No Yes 
Diarrhea No No Yes Yes No No 
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*intended as last KT 
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Table 2. Laboratory and pulmonary functional tests before and after TCZ adoption in our COVID-19 positive kidney transplant recipients 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
C-reactive protein (mg/L)       
Before TCZ 170.4 90.2 154.7 32 49.8 71.4 
Day 3 after TCZ 35.4 20.3 44.6 12 23.7 8.6 
At last f/up 3.6 34.9 2.24 10 0.6 2.4 
       
Procalcitonine (ng/mL)       
Before TCZ 24.1 0.19 0.18 0.12 0.43 0.4 
Day 3 after TCZ 1.02 0.1 0.3 0.13  0.29 NA 
At last f/up 0.17 0.73 0.07 0.15 0.06 0.45 
       
Whyte-cell count [lymphocyte] (per mm
3
)       
Before TCZ 9930 [400] 7240 [370] 4380 [610] 13660 [230] 4130 [300] 7890 [480] 
Day 3 after TCZ 11300 [230] 6270 [310] 4020 [800] 21790 [400] 4370 [330] 4110 [140] 
At last f/up 6390 [850] 11720 [410] 3770 [950] 36890 [800] 6440 [1030] 10420 [380] 
       
Lactate dehydrogenase (UI/L)       
Before TCZ 771  518 652 704 573 1068 
Day 3 after TCZ 496 792 765 565 762 816 
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D-Dimer (ng/mL)       
Before TCZ 12552 707 730 3188 876 351 
Day 3 after TCZ 18111 1497 840 2873 2020 <215 
At last f/up 1565 2032 500 2842 1468 281 
       
Ferritin (ng/ml)       
Before TCZ 1754 523 NA 830 1567 955 
Day 3 after TCZ 1108 847 NA 637 1065 767 
At last f/up 1310 906 NA 840 371 NA 
 
IL-6 (pg/mL)       
Before TCZ NA NA 24.9* 465** NA 312.5** 
Day 3 after TCZ NA NA 188.7* 564.5** NA 282.7** 
At last f/up NA NA 63.3* 1077.6** NA NA 
Pa02/Fi02 (mmHg)       
Before TCZ 115 291 333 300 83 182 
Day 3 after TCZ 135 203 256 111 291 265 
At last f/up 92 87 493 170 347 187 
TCZ: tocilizumab; PaO2: partial pressure of oxygen; FiO2: fraction of inspired oxygen 









**normal range 2-29 
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Table 3. Kidney transplant recipients with COVID-19 treated with tocilizumab (Pubmed update on 05/09/2020) 
Author Patients, n 
(studied 
population) 
Criteria for tocilizumab 
adoption 
Dose, mg (n) Pulmonary 
outcome 




 1 (1) Progressive respiratory failure 
+ increasing inflammatory 
parameters 







 6 (20) Worsening of respiratory 
infection 
8 mg/kg iv, 
max 800 mg 
(two doses, intervals 
12-24 hours) 













 1 (1) PFTs deterioration 
+ elevated IL-6 











 14 (90)** Rapid pulmonary 
decompensation due to high 
and deleterious cytokine 
activity 
400 mg sc or 8 
mg/kg iv, max 800 
mg 
 (9/14 one dose,  
NA 3/14 death 
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4/14 two doses, 
1/14 three doses) 
iv: intravenous; sc: subcutaneous; NA: not available; ICU: intensive care unit 
*inpatient group 
**46/90 kidney tranplants 
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